Fate Therapeutics, Inc. (NASDAQ:FATE – Get Rating) Director Redmile Group, Llc purchased 25,700 shares of the firm’s stock in a transaction on Friday, April 14th. The stock was bought at an average cost of $6.00 per share, with a total value of $154,200.00. Following the completion of the acquisition, the director now directly owns 12,859,119 shares of the company’s stock, valued at approximately $77,154,714. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

NASDAQ FATE opened at $6.23 on Wednesday. The business has a fifty day moving average price of $5.82 and a 200 day moving average price of $11.83. Fate Therapeutics, Inc. has a one year low of $4.02 and a one year high of $38.69. The company has a market cap of $611.54 million, a P/E ratio of -2.14 and a beta of 1.49.

Fate Therapeutics (NASDAQ:FATE – Get Rating) last issued its earnings results on Tuesday, February 28th. The biopharmaceutical company reported ($0.58) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.86) by $0.28. Fate Therapeutics had a negative return on equity of 50.86% and a negative net margin of 292.55%. The business had revenue of $44.36 million during the quarter, compared to the consensus estimate of $18.41 million. During the same period last year, the company earned ($0.72) EPS. The company’s revenue for the quarter was up 159.9% on a year-over-year basis.  As a group, sell-side analysts predict that  Fate Therapeutics, Inc. will post -2 EPS for the current fiscal year.

FATE has been the subject of a number of analyst reports. Cowen downgraded Fate Therapeutics from an “outperform” rating to a “market perform” rating in a report on Friday, January 6th. Cantor Fitzgerald downgraded Fate Therapeutics from an “overweight” rating to a “neutral” rating in a report on Monday, January 9th. Truist Financial  reissued a “hold” rating and issued a $7.00 price target (down from $46.00) on shares of Fate Therapeutics in a report on Friday, January 6th. StockNews.com raised Fate Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, April 12th. Finally, Wells Fargo & Company  reaffirmed an “equal weight” rating and set a $6.00 target price on shares of Fate Therapeutics in a research note on Monday, March 27th. Two research analysts have rated the stock with a sell rating, sixteen have given a hold rating and five have issued  a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $19.44.

A number of hedge funds and other institutional investors have recently modified their holdings of FATE. Envestnet Asset Management Inc. increased its stake in shares of  Fate Therapeutics by 20.0% in the 1st quarter. Envestnet Asset Management Inc. now owns 8,734 shares of the biopharmaceutical company’s stock worth $339,000 after acquiring an additional 1,457 shares during the last quarter.  Raymond James & Associates increased its stake in shares of  Fate Therapeutics by 42.6% in the 1st quarter. Raymond James & Associates now owns 29,436 shares of the biopharmaceutical company’s stock worth $1,141,000 after acquiring an additional 8,790 shares during the last quarter.  HighTower Advisors LLC increased its stake in shares of  Fate Therapeutics by 5.9% in the 1st quarter. HighTower Advisors LLC now owns 18,361 shares of the biopharmaceutical company’s stock worth $714,000 after acquiring an additional 1,016 shares during the last quarter.  Private Advisor Group LLC grew its holdings in shares of  Fate Therapeutics by 25.7% during the 1st quarter. Private Advisor Group LLC now owns 9,481 shares of the biopharmaceutical company’s stock worth $367,000 after purchasing an additional 1,938 shares during the period.  Finally, PNC Financial Services Group Inc. grew its holdings in shares of  Fate Therapeutics by 17.1% during the 1st quarter. PNC Financial Services Group Inc. now owns 6,737 shares of the biopharmaceutical company’s stock worth $260,000 after purchasing an additional 986 shares during the period.

Fate Therapeutics, Inc engages in the development of programmed cellular immunotherapies for cancer and immune disorder. Its pipeline of products includes immuno-ocology candidates and immuno-regulation candidates. The company was founded by Philip Beachy, Sheng Ding, Rudolf Jaenisch, Randall T. Moon, Michael Rudnicki, David Scadden, Leonard Zon, Alexander Rives, Scott Wolchko, and John D.

Receive News & Ratings for Fate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.